122 related articles for article (PubMed ID: 36715017)
1. Autoimmune diseases as comorbidities for liver, gallbladder, and biliary duct cancers in Sweden.
Hemminki K; Sundquist K; Sundquist J; Försti A; Liska V; Hemminki A; Li X
Cancer; 2023 Jan; ():. PubMed ID: 36715017
[TBL] [Abstract][Full Text] [Related]
2. Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers.
Hemminki K; Sundquist K; Sundquist J; Försti A; Liska V; Hemminki A; Li X
Int J Cancer; 2023 Mar; 152(6):1107-1114. PubMed ID: 36196489
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease.
Castro FA; Liu X; Försti A; Ji J; Sundquist J; Sundquist K; Koshiol J; Hemminki K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1038-45.e7. PubMed ID: 24246767
[TBL] [Abstract][Full Text] [Related]
4. Population-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancers.
Hemminki K; Sundquist K; Sundquist J; Försti A; Liska V; Hemminki A; Li X
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370702
[TBL] [Abstract][Full Text] [Related]
5. Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country.
Hemminki K; Sundquist K; Sundquist J; Försti A; Liska V; Hemminki A; Li X
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454845
[TBL] [Abstract][Full Text] [Related]
6. Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults.
McGee EE; Castro FA; Engels EA; Freedman ND; Pfeiffer RM; Nogueira L; Stolzenberg-Solomon R; McGlynn KA; Hemminki K; Koshiol J
Int J Cancer; 2019 Feb; 144(4):707-717. PubMed ID: 30155920
[TBL] [Abstract][Full Text] [Related]
7. Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers.
Zheng G; Sundquist K; Sundquist J; Chen T; Försti A; Hemminki A; Liska V; Hemminki K
Clin Epidemiol; 2021; 13():683-691. PubMed ID: 34377034
[TBL] [Abstract][Full Text] [Related]
8. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures.
Rizzo A; Tavolari S; Ricci AD; Frega G; Palloni A; Relli V; Salati M; Fenocchio E; Massa A; Aglietta M; Brandi G
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33158162
[TBL] [Abstract][Full Text] [Related]
9. Aspirin, Statins, Non-aspirin NSAIDs, Metformin, and the Risk of Biliary Cancer: A Swedish Population-Based Cohort Study.
Marcano-Bonilla L; Schleck CD; Harmsen WS; Sadr-Azodi O; Borad MJ; Patel T; Petersen GM; Therneau TM; Roberts LR; Brusselaers N
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):804-810. PubMed ID: 35086822
[TBL] [Abstract][Full Text] [Related]
10. Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States.
Storandt MH; Tella SH; Wieczorek MA; Hodge D; Elrod JK; Rosenberg PS; Jin Z; Mahipal A
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398075
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis--a long-term follow-up study in 634 Swedish patients.
Danielsson Borssén Å; Almer S; Prytz H; Wallerstedt S; Friis-Liby IL; Bergquist A; Nyhlin N; Hultcrantz R; Sangfelt P; Weiland O; Lindgren S; Verbaan H; Werner M
Scand J Gastroenterol; 2015 Feb; 50(2):217-23. PubMed ID: 25483724
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
[TBL] [Abstract][Full Text] [Related]
13. Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study.
Yu J; Refsum E; Helsingen LM; Folseraas T; Ploner A; Wieszczy P; Barua I; Jodal HC; Melum E; Løberg M; Blom J; Bretthauer M; Adami HO; Kalager M; Ye W
United European Gastroenterol J; 2022 Mar; 10(2):212-224. PubMed ID: 35107865
[TBL] [Abstract][Full Text] [Related]
14. Gall bladder cancer, extrahepatic bile duct cancer and ampullary carcinoma in New Zealand: Demographics, pathology and survival.
Koea J; Phillips A; Lawes C; Rodgers M; Windsor J; McCall J
ANZ J Surg; 2002 Dec; 72(12):857-61. PubMed ID: 12485219
[TBL] [Abstract][Full Text] [Related]
15. Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002.
Goodman MT; Yamamoto J
Cancer Causes Control; 2007 May; 18(4):415-22. PubMed ID: 17264972
[TBL] [Abstract][Full Text] [Related]
16. New epidemiologic trends in cholangiocarcinoma.
Pascale A; Rosmorduc O; Duclos-Vallée JC
Clin Res Hepatol Gastroenterol; 2023 Nov; 47(9):102223. PubMed ID: 37797807
[TBL] [Abstract][Full Text] [Related]
17. Incidence and mortality trends for biliary tract cancers in Austria.
Pinter M; Hucke F; Zielonke N; Waldhör T; Trauner M; Peck-Radosavljevic M; Sieghart W
Liver Int; 2014 Aug; 34(7):1102-8. PubMed ID: 24119058
[TBL] [Abstract][Full Text] [Related]
18. Excess risk of primary liver cancer in patients with diabetes mellitus.
Adami HO; Chow WH; Nyrén O; Berne C; Linet MS; Ekbom A; Wolk A; McLaughlin JK; Fraumeni JF
J Natl Cancer Inst; 1996 Oct; 88(20):1472-7. PubMed ID: 8841022
[TBL] [Abstract][Full Text] [Related]
19. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.
Wongjarupong N; Assavapongpaiboon B; Susantitaphong P; Cheungpasitporn W; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
BMC Gastroenterol; 2017 Dec; 17(1):149. PubMed ID: 29216833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
